Trial Profile
A Phase Ib/II Study of Cisplatin, Paclitaxel, and RAD001 in Patients with Metastatic Breast Cancer (SPORE).
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 09 Nov 2021
Price :
$35
*
At a glance
- Drugs Cisplatin (Primary) ; Everolimus (Primary) ; Paclitaxel (Primary)
- Indications Advanced breast cancer; Male breast cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms SPORE
- 03 Aug 2018 Status changed from active, no longer recruiting to completed.
- 24 Jul 2017 Planned End Date changed from 1 Jan 2017 to 1 Jul 2018.
- 18 Jul 2016 Planned End Date changed from 1 Jan 2014 to 1 Jan 2017.